{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:01Z","timestamp":1791181441813,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"crossref","award":["V104C-182"],"award-info":[{"award-number":["V104C-182"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100009096","name":"Taiwan Clinical Oncology Research Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009096","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Chong Hin Loon Memorial Cancer and Biotherapy Research Cancer, National Yang-Ming University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.bcmd.2015.03.009","type":"journal-article","created":{"date-parts":[[2015,4,5]],"date-time":"2015-04-05T21:41:56Z","timestamp":1428270116000},"page":"36-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["No increase of JAK2 46\/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation"],"prefix":"10.1016","volume":"55","author":[{"given":"Jyh-Pyng","family":"Gau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Sheng","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Bin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang-Tsai","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Hwang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzeon-Jye","family":"Chiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Min","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hwai","family":"Tzeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2015.03.009_bb0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MOH.0b013e328343998e","article-title":"Genetics of the myeloproliferative neoplasms","volume":"18","author":"Abdel-Wahab","year":"2011","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0010","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0015","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0020","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa0810069","article-title":"Mutation in TET2 in myeloid cancers","volume":"360","author":"Delhommeau","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1038\/ng.621","article-title":"Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders","volume":"42","author":"Ernst","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0030","doi-asserted-by":"crossref","first-page":"6182","DOI":"10.1182\/blood-2008-12-194548","article-title":"Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms","volume":"113","author":"Grand","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0035","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0045","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0050","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ng.334","article-title":"JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms","volume":"41","author":"Jones","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/ng.342","article-title":"A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms","volume":"41","author":"Kilpivaara","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/ng.341","article-title":"A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasms","volume":"41","author":"Olcaydu","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0065","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/ng0409-385","article-title":"Somatic and germline genetics at the JAK2 locus","volume":"41","author":"Campbell","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0070","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0075","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/leu.2009.225","article-title":"JAK2 germline genetic variation affects disease susceptibility in primary myelofibrosis regardless of V617F mutational status: nullizygosity for the JAK2 46\/1 haplotype is associated with inferior survival","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0080","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2009-08-236448","article-title":"The JAK2 46\/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasms","volume":"115","author":"Jones","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0085","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1007\/s00277-014-2151-8","article-title":"Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia","volume":"93","author":"Chen","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.bcmd.2015.03.009_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/leu.2009.226","article-title":"The JAK2 46\/1 haplotype confers susceptibility to essential thrombocythemia regardless of JAK2V617F mutational status-clinical correlates in a study of 226 consecutive patients","volume":"24","author":"Pardanani","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0095","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/leu.2013.21","article-title":"JAK2V617F allele burden, JAK2 46\/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0100","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood-2011-11-389866","article-title":"Unique features of primary myelofibrosis in Chinese","volume":"119","author":"Xu","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0105","article-title":"Genetic and functional investigation of germline JAK2 alleles that predispose to myeloproliferative neoplasms","volume":"118","author":"Schram","year":"2011","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0110","article-title":"Homologous recombination of wild type JAK2, a novel early step in the development of myeloproliferative neoplasm","volume":"118","author":"Valaine","year":"2011","journal-title":"Blood (ASH Annu. Meet. Abstr.)"},{"key":"10.1016\/j.bcmd.2015.03.009_bb0115","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615000698?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979615000698?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:30:58Z","timestamp":1761049858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979615000698"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S1079979615000698"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.03.009","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No increase of JAK2 46\/1 haplotype frequency in essential thrombocythemia with CALR mutations: Functional effect of the haplotype limited to allele with JAK2V617F mutation but not CALR mutation","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2015.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}